Is the use of unfractionated heparin in acute coronary syndrome outmoded?

Elaine Chiquette, Robert J Chilton

Research output: Contribution to journalArticle

Abstract

Because of the key role of thrombin in the pathogenesis of acute coronary syndrome (ACS), the appropriate selection of antithrombotic therapy is important. Unfractionated herapin (UFH) has been the agent of choice for decades. Unfortunately, UFH has a number of limitations related to its pharmacokinetic and pharmacodynamic properties. Low molecular weight herapins (LMWHs) are attractive alternatives to UFH for several reasons, including predictable anticoagulation and ease of administration. Two LMWhs (dalteparin and enoxaparin) have been approved as alternatives to UFH in patients presenting with unstable angina and non-ST-segment elevation myocardial infarction. Randomized, controlled trials, in addition to open-label series, indicate that LMWH can safety be the agent of choice with or without glycoprotein llb/llla in the medical and upstream management of patients with ACS. Although the data are not definitive, several trials suggest that given intravenously, enoxaparin is safe as the sole antithrombotic agent in the catheterization laboratory.

Original languageEnglish (US)
Pages (from-to)94-100
Number of pages7
JournalCurrent Atherosclerosis Reports
Volume6
Issue number2
StatePublished - Mar 2004

Fingerprint

Enoxaparin
Acute Coronary Syndrome
Heparin
Molecular Weight
Dalteparin
Fibrinolytic Agents
Unstable Angina
Thrombin
Catheterization
Glycoproteins
Randomized Controlled Trials
Pharmacokinetics
Safety
Therapeutics
Non-ST Elevated Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Is the use of unfractionated heparin in acute coronary syndrome outmoded? / Chiquette, Elaine; Chilton, Robert J.

In: Current Atherosclerosis Reports, Vol. 6, No. 2, 03.2004, p. 94-100.

Research output: Contribution to journalArticle

Chiquette, Elaine ; Chilton, Robert J. / Is the use of unfractionated heparin in acute coronary syndrome outmoded?. In: Current Atherosclerosis Reports. 2004 ; Vol. 6, No. 2. pp. 94-100.
@article{9e3f6d9078fa46578c1d41c21780dae4,
title = "Is the use of unfractionated heparin in acute coronary syndrome outmoded?",
abstract = "Because of the key role of thrombin in the pathogenesis of acute coronary syndrome (ACS), the appropriate selection of antithrombotic therapy is important. Unfractionated herapin (UFH) has been the agent of choice for decades. Unfortunately, UFH has a number of limitations related to its pharmacokinetic and pharmacodynamic properties. Low molecular weight herapins (LMWHs) are attractive alternatives to UFH for several reasons, including predictable anticoagulation and ease of administration. Two LMWhs (dalteparin and enoxaparin) have been approved as alternatives to UFH in patients presenting with unstable angina and non-ST-segment elevation myocardial infarction. Randomized, controlled trials, in addition to open-label series, indicate that LMWH can safety be the agent of choice with or without glycoprotein llb/llla in the medical and upstream management of patients with ACS. Although the data are not definitive, several trials suggest that given intravenously, enoxaparin is safe as the sole antithrombotic agent in the catheterization laboratory.",
author = "Elaine Chiquette and Chilton, {Robert J}",
year = "2004",
month = "3",
language = "English (US)",
volume = "6",
pages = "94--100",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - Is the use of unfractionated heparin in acute coronary syndrome outmoded?

AU - Chiquette, Elaine

AU - Chilton, Robert J

PY - 2004/3

Y1 - 2004/3

N2 - Because of the key role of thrombin in the pathogenesis of acute coronary syndrome (ACS), the appropriate selection of antithrombotic therapy is important. Unfractionated herapin (UFH) has been the agent of choice for decades. Unfortunately, UFH has a number of limitations related to its pharmacokinetic and pharmacodynamic properties. Low molecular weight herapins (LMWHs) are attractive alternatives to UFH for several reasons, including predictable anticoagulation and ease of administration. Two LMWhs (dalteparin and enoxaparin) have been approved as alternatives to UFH in patients presenting with unstable angina and non-ST-segment elevation myocardial infarction. Randomized, controlled trials, in addition to open-label series, indicate that LMWH can safety be the agent of choice with or without glycoprotein llb/llla in the medical and upstream management of patients with ACS. Although the data are not definitive, several trials suggest that given intravenously, enoxaparin is safe as the sole antithrombotic agent in the catheterization laboratory.

AB - Because of the key role of thrombin in the pathogenesis of acute coronary syndrome (ACS), the appropriate selection of antithrombotic therapy is important. Unfractionated herapin (UFH) has been the agent of choice for decades. Unfortunately, UFH has a number of limitations related to its pharmacokinetic and pharmacodynamic properties. Low molecular weight herapins (LMWHs) are attractive alternatives to UFH for several reasons, including predictable anticoagulation and ease of administration. Two LMWhs (dalteparin and enoxaparin) have been approved as alternatives to UFH in patients presenting with unstable angina and non-ST-segment elevation myocardial infarction. Randomized, controlled trials, in addition to open-label series, indicate that LMWH can safety be the agent of choice with or without glycoprotein llb/llla in the medical and upstream management of patients with ACS. Although the data are not definitive, several trials suggest that given intravenously, enoxaparin is safe as the sole antithrombotic agent in the catheterization laboratory.

UR - http://www.scopus.com/inward/record.url?scp=3142686084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142686084&partnerID=8YFLogxK

M3 - Article

C2 - 15023292

AN - SCOPUS:3142686084

VL - 6

SP - 94

EP - 100

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 2

ER -